Abstract GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel
antidiabetic medications associated with considerable cardiovascular benefits therapying …

Diabetes and obesity are growing problems worldwide and are associated with a range of
acute and chronic complications, including acute myocardial infarction (AMI) and stroke …

With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of
type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin …

Heart failure and cognitive impairment emerge as public health problems that need to be
addressed due to the aging global population. The conditions that often coexist are strongly …

Abstract Purpose of Review In addition to their effects on glycemic control, two specific
classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 …

During the last decade, the results of large-scale, randomized, clinical trials on newer
antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose …

Sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 receptor
(GLP-1-R) agonists are novel therapeutic agents used for the management of type 2 …

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central
in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with …

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers
blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor …

SGLT2 inhibitors (SGLT2is) have been developed to lower blood glucose. They were
subsequently found to be beneficial in other conditions that lead to the recent …